dc.contributor.author | Kononova, Natalia | |
dc.contributor.author | Einvik, Gunnar | |
dc.contributor.author | Holmedahl, Nils H. | |
dc.contributor.author | Hagve, Tor-Arne | |
dc.contributor.author | Omland, Torbjørn | |
dc.contributor.author | Søyseth, Vidar | |
dc.date.accessioned | 2022-11-08T06:02:23Z | |
dc.date.available | 2022-11-08T06:02:23Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | BMC Pulmonary Medicine. 2022 Nov 01;22(1):392 | |
dc.identifier.uri | http://hdl.handle.net/10852/97530 | |
dc.description.abstract | Background
Cardiac troponin T (cTnT) is a biomarker of myocardial injury frequently elevated in COPD patients, potentially because of hypoxemia. This non-randomised observational study investigates whether long-term oxygen treatment (LTOT) reduces the cTnT level.
Methods
We compared cTnT between COPD patients who were candidates for LTOT (n = 20) with two reference groups. Patients from both reference groups were matched with the index group using propensity score.Reference groups consists of institutional pulmonary rehabilitation patients (short-term group) (n = 105 after matching n = 11) and outpatients at a pulmonary rehabilitation clinic (long-term group)(n = 62 after matching n = 10). Comparison was done within 24 h after LTOT initiation in first reference group and within 6 months after inclusion in the second group.
Results
The geometric mean of (standard deviation in parentheses) cTnT decreased from 17.8 (2.3) ng/L (between 8 and 9 a.m.) to 15.4 (2.5) ng/L between 1 and 2 p.m. in the LTOT group, and from 18.4 (4.8) ng/L to15.4 (2.5) ng/L in group (1) The corresponding long-term results were 17.0 (2.9) ng/L at inclusion (between 10 and 12 a.m.) to 18.4 (2.4) ng/L after 3 months in the LTOT-group, and from 14.0 (2.4) ng/L to 15.4 (2.5) ng/L after 6 months in group (2) None of the differences in cTnT during the follow-up between the LTOT-group and their matched references were significant.
Conclusion
Initiation of LTOT was not associated with an early or sustained reduction in cTnT after treatment with oxygen supplementation. | |
dc.language.iso | eng | |
dc.rights | The Author(s) | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.title | It is unlikely that oxygen supplementation in COPD patients with chronic respiratory failure reduce cardiac troponin level | |
dc.type | Journal article | |
dc.date.updated | 2022-11-08T06:02:23Z | |
dc.creator.author | Kononova, Natalia | |
dc.creator.author | Einvik, Gunnar | |
dc.creator.author | Holmedahl, Nils H. | |
dc.creator.author | Hagve, Tor-Arne | |
dc.creator.author | Omland, Torbjørn | |
dc.creator.author | Søyseth, Vidar | |
dc.identifier.cristin | 2077238 | |
dc.identifier.doi | https://doi.org/10.1186/s12890-022-02169-7 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.type.version | PublishedVersion | |
cristin.articleid | 392 | |